Zyprexa Relprevv approved for treatment of schizophrenia in adults

Zyprexa Relprevv (extended-release olanzapine injectable suspension, from Lilly) has been FDA approved for the treatment of schizophrenia in adults. This approval is based on a broad clinical data package involving 2,054 patients, in which Zyprexa Relprevv was found to be effective in controlling symptoms of schizophrenia, including hallucinations, delusions, apathy and social withdrawal. Efficacy was shown without the need for oral supplementation. Clinical data showed that Zyprexa Relprevv dosages (150, 210, 300 and 405 mg) provide therapeutic olanzapine exposure for two or four weeks depending on the dose.

Zyprexa tablets and Zyprexa Zydis are already indicated in adults for the treatment of schizophrenia, acute treatment of mixed and manic episodes of bipolar I disorder, and maintenance treatment of bipolar I disorder.  Additionally, the oral formulations were also recently approved for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adolescents 13–17 years of age. Zyprexa Intramuscular injection is indicated for the treatment of agitation caused either by schizophrenia or bipolar I disorder.  

For more information call (800) 545-5979 or visit www.zyprexa.com.